Dementia Big
Axovant Sciences today announced that the Phase 3 MINDSET trial of its Alzheimer’s drug intepirdine has failed to bring meaningful improvements in cognition or daily functioning.
http://ift.tt/2y6BQNR
Tuesday, September 26, 2017
Intepirdine fails to treat Alzheimer’s disease in Phase 3 trial
Intepirdine fails to treat Alzheimer’s disease in Phase 3 trial:
http://ift.tt/2y6BQNR
http://ift.tt/2y6BQNR
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment